• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioArctic

309.40 SEK+0.85 %24/7 17:29
Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.85 %
-1.09 %
-3.49 %
-0.51 %
-0.45 %
+40.76 %
+1.64 %
+116.36 %
+966.90 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Read more
Market cap
27.45B SEK
Turnover
14.54M SEK
Revenue
2B
EBIT %
62.97 %
P/E
26.79
Dividend yield-%
0.65 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually...
8/28/2025, 10:21 AM
by Hawkmountdiver
7
About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.
8/28/2025, 2:16 PM
by j.sälli
2
Brand new Q2 / 2025 below. bioarctic.com wkr0006-146.pdf 1682.08 KB
8/28/2025, 10:28 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

25/11
2026

Interim report Q3'26

17/2
2027

Annual report '26

Press release2026-07-14 17:15

BioArctic: More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BioArctic
Press release2026-07-14 17:15

BioArctic: Mer än 75 % av patienterna som behandlats med Leqembi® förblev stabila och nära 7 % förbättrades efter i genomsnitt 17 månaders behandling visar data från LEADER-studien som presenterats på AAIC® 2026

BioArctic
Regulatory press release2026-07-13 23:55

BioArctic: FDA godkänner Leqembi Iqlik® (lecanemab-irmb) som subkutan startbehandling vid tidig Alzheimers sjukdom

BioArctic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-07-13 23:55

BioArctic: FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

BioArctic
Press release2026-07-12 17:30

BioArctic: Nya kliniska data för Leqembi® subkutan autoinjektor presenterade vid AAIC® 2026 visar på effekt och säkerhet jämförbar med intravenös formulering vid tidig Alzheimers sjukdom

BioArctic
Press release2026-07-12 17:30

BioArctic: New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

BioArctic
Press release2026-06-30 08:00

BioArctic: Nya behandlingsdata för lecanemab i klinisk vardag kommer att presenteras vid AAIC-kongressen 2026

BioArctic
Press release2026-06-30 08:00

BioArctic: New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

BioArctic
Press release2026-06-23 09:21

Investor Studios: BioArctics VD intervjuas om Eli Lilly-avtalet live 11.00

BioArctic
Regulatory press release2026-06-22 07:32

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

BioArctic
Regulatory press release2026-06-22 07:32

BioArctic och Lilly ingår avtal för att kombinera läkemedelskandidat från Lilly med BioArctics BrainTransporter™

BioArctic
Regulatory press release2026-05-29 18:30

Antal aktier och röster i BioArctic AB (publ) per den 29 maj 2026

BioArctic
Regulatory press release2026-05-29 18:30

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

BioArctic
Regulatory press release2026-05-28 18:30

Bulletin from the Annual General Meeting in BioArctic AB (publ)

BioArctic
Regulatory press release2026-05-28 18:30

Kommuniké från årsstämma i BioArctic AB (publ)

BioArctic
Regulatory press release2026-05-25 09:15

BioArctics partner Eisai presenterar simulering av potentiell framtida försäljning av Leqembi® vid sin kapitalmarknadsdag (Investor Relations Day)

BioArctic
Regulatory press release2026-05-25 09:15

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BioArctic
BioArctic, Audiocast, Q1'26
Webcast2026-05-20 09:30

BioArctic, Audiocast, Q1'26

BioArctic
Regulatory press release2026-05-20 07:00

Delårsrapport januari - mars 2026

BioArctic
Regulatory press release2026-05-20 07:00

Interim Report for the period January - March 2026

BioArctic